top of page
Publications & Presentations
Rademikibart - Respiratory
Rapid and Sustained FEV1 improvements with Rademikibart in Type 2 Asthma: Impact of Eosinophils and FeNO
Presented at the 2025 European Respiratory Society (ERS) Congress, September 27 to Oct 1, 2025
Rademikibart in Moderate-to-Severe Asthma: Impact of Eosinophils and Regional Differences on Response
Presented at the 2025 European Respiratory Society (ERS) Congress, September 27 to Oct 1, 2025
Reduction in Annualized Exacerbations with Rademikibart in Eosinophilic-driven Type 2 Asthma
Presented at the 2025 European Association of Allergy and Clinical Immunology (EAACI) Congress, June 13 to 16, 2025
Optimized Second-generation IL-4Rα Inhibition: Structural and Molecular Dynamics Properties of the Rademikibart Fab-IL-4Rα Complex
Presented at the American Thoracic Society (ATS) Congress, May 16-21, 2025
Effect of Rademikibart on Blood Eosinophil Counts in Patients with Asthma: Is there an IL-4Rα Class Effect?
Presented at the American Thoracic Society (ATS) Congress, May 16-21, 2025
Rapid Improvement in Lung Function Observed with Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma
Presented at the American Thoracic Society (ATS) Congress, May 16-21, 2025
Efficacy of Rademikibart in COPD-like Patients: Sub-analyses from the Phase 2b Trial in Patients with Moderate-to-Severe Asthma
Presented at the American Thoracic Society (ATS) Congress, May 16-21, 2025
Improved lung function and asthma control observed with rademikibart in patients with moderate-to-severe asthma
Oral presentation at the European Respiratory Society (ERS) Congress, September 7-11, 2024
bottom of page